AMPHIVENA THERAPEUTICS

amphivena-therapeutics-logo

Amphivena Therapeutics is a clinical-stage immuno-oncology company that develops a platform of dual-function biologics. Its Amphivena ReSTORE platform provides dual-action biologics that relieve immune suppression and activate T cell effector function in cancer patients. The platform design integrates elements of avidity, target selectivity, and enhanced safety within a single molecule. It is also can be engineered with additional solid tumor targeting modalities to add functionality such as directed tumor cell killing. It was founded in 2012 and is headquartered in South San Francisco, California.

#SimilarOrganizations #People #Financial #Event #Website #More

AMPHIVENA THERAPEUTICS

Social Links:

Industry:
Biotechnology Health Care Oncology Therapeutics

Founded:
2012-01-01

Address:
South San Francisco, California, United States

Country:
United States

Website Url:
http://www.amphivena.com

Total Employee:
11+

Status:
Active

Contact:
415-994-6455

Email Addresses:
[email protected]

Total Funding:
135.69 M USD

Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Domain Not Resolving WordPress Google Maps SSL By Default HSTS IPv6 Cloudflare Hosting Sitelinks Search Box


Similar Organizations

acrivon-therapeutics-logo

Acrivon Therapeutics

Acrivon Therapeutics is a precision oncology therapeutics company specializing in drug development through early clinical treatment success.

avstera-therapeutics-logo

Avstera Therapeutics

Avstera Therapeutics is an oncology-focused biotech company that fulfil unmet needs of cancer patients.

enliven-therapeutics-logo

Enliven Therapeutics

Enliven Therapeutics is a precision oncology company developing small molecule therapies to extend and improve patient lives.

forty-seven-logo

Forty Seven

Forty Seven is a clinical-stage immuno-oncology company that is developing therapies targeting cancer immune evasion pathways.

gritstone-bio-logo

Gritstone Bio

Gritstone Oncology is a clinical-stage biotech company that develops tumor-specific cancer immunotherapies to fight multiple cancer types.

pinpoint-therapeutics-logo

Pinpoint Therapeutics

Pinpoint Therapeutics is a preclinical stage company developing novel cancer treatment options aimed to specifically inhibit autophagy.

scout-bio-logo

Scout Bio

Scout Bi is a biotechnology company that provides veterinary, animal health, and gene therapy.

tmunity-therapeutics-logo

Tmunity Therapeutics

Tmunity Therapeutics is developing novel products to unleash the immunological potential of T cells

vor-biopharma-logo

Vor Biopharma

Vor Biopharma is an immuno-oncology company that develops therapies for treating cancer.


Current Advisors List

vin-bhaskar_image

Vin Bhaskar Board Of Directors @ Amphivena Therapeutics
Board_member
2017-01-01

Current Employees Featured

not_available_image

Victoria Smith, PH.D.
Victoria Smith, PH.D. Chief Scientific Officer @ Amphivena Therapeutics
Chief Scientific Officer

not_available_image

Patric Chun, M.D.
Patric Chun, M.D. Vice President Clinical Development @ Amphivena Therapeutics
Vice President Clinical Development

not_available_image

Amy Penticoff, MBA
Amy Penticoff, MBA Vice President Technical Operations @ Amphivena Therapeutics
Vice President Technical Operations

Founder


luke-evnin_image

Luke Evnin

Investors List

qiming-venture-partners_image

Qiming Venture Partners

Qiming Venture Partners investment in Series C - Amphivena Therapeutics

nd-capital_image

+ND Capital

+ND Capital investment in Series C - Amphivena Therapeutics

industrial-investors-group_image

Industrial Investors Group

Industrial Investors Group investment in Series C - Amphivena Therapeutics

solasta-ventures_image

Solasta Ventures

Solasta Ventures investment in Series C - Amphivena Therapeutics

clough-capital-partners_image

Clough Capital Partners

Clough Capital Partners investment in Series C - Amphivena Therapeutics

franklin-m-berger_image

Franklin Berger

Franklin Berger investment in Series C - Amphivena Therapeutics

newton-investment-management_image

Newton Investment Management

Newton Investment Management investment in Series C - Amphivena Therapeutics

mérieux-equity-partners_image

Mérieux Equity Partners

Mérieux Equity Partners investment in Series C - Amphivena Therapeutics

aju-ib-investment_image

Aju IB Investment

Aju IB Investment investment in Series C - Amphivena Therapeutics

mpm-capital_image

MPM Capital

MPM Capital investment in Series C - Amphivena Therapeutics

Key Employee Changes

Date New article
2019-12-02 Amphivena Therapeutics appoints president and CEO

Official Site Inspections

http://www.amphivena.com

  • Host name: 104.21.43.46
  • IP address: 104.21.43.46
  • Location: United States
  • Latitude: 37.751
  • Longitude: -97.822
  • Timezone: America/Chicago

Loading ...

More informations about "Amphivena Therapeutics"

Amphivena Therapeutics - Crunchbase Company …

Amphivena Therapeutics is a clinical-stage immuno-oncology company that develops a platform of dual-function biologics. Its Amphivena ReSTORE …See details»

Amphivena Therapeutics Company Profile 2024: …

Nov 21, 2017 Amphivena Therapeutics was founded in 2012. Where is Amphivena Therapeutics headquartered? Amphivena Therapeutics is …See details»

Amphivena Therapeutics Inc - LinkedIn

Amphivena Therapeutics is a clinical-stage immuno-oncology company that develops a platform of dual-function biologics. Its Amphivena ReSTORE platform provides dual-action biologics …See details»

Amphivena Therapeutics - Funding, Financials, Valuation & Investors

Amphivena Therapeutics is funded by 14 investors. Qiming Venture Partners and +ND Capital are the most recent investors. Amphivena Therapeutics has a post-money valuation in the range …See details»

Amphivena Therapeutics - Contacts, Employees, Board Members, …

Organization. Amphivena Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. ... About. Amphivena Therapeutics has 3 current employee …See details»

Amphivena Therapeutics, Inc. - Drug pipelines, Patents, Clinical …

Explore Amphivena Therapeutics, Inc. with its drug pipeline, therapeutic area, technology platform, 3 clinical trials, 7 news, and 11 literature, Drug:AMV300, AMV900, AMV600, …See details»

Amphivena Therapeutics - Craft

Amphivena Presents Translational Data Highlighting the Cytokine Profile for its Lead Clinical Candidate, AMV564 at the AACR 2021 Virtual Annual Meeting. Apr 12, 2021. Amphivena …See details»

Amphivena Therapeutics (USA) Funding: $135.7M

Nov 7, 2024 USA | Funding: $135.7M Website: http://amphivena.com/ Amphivena Therapeutics develops treatments to address hematologic malignancies.See details»

Amphivena Therapeutics, Inc. Details

Amphivena Therapeutics, Inc. is a clinical stage, immuno oncology company with a novel platform of T cell engagers (Amphivena ReSTORE™) that directly targets myeloid derived suppressor …See details»

Amphivena Therapeutics, Inc. (Amphivena Therapeutics, Inc.) - 药 …

了解Amphivena Therapeutics, Inc. (Amphivena Therapeutics, Inc.)公司的药物管线,治疗领域,技术平台,以及它的3项临床试验, 9篇新闻和2篇文献,药 …See details»

Amphivena Therapeutics | VentureRadar

Amphivena Therapeutics, in collaboration with Affimed AG, is developing bispecific TandAbs for hematologic malignancies. TandAbs are tetravalent bispecific antibody formats (~100kD) that …See details»

Amphivena Therapeutics - Tech Stack, Apps, Patents & Trademarks

Amphivena Therapeutics uses 14 technology products and services including HTML5, Modernizr, and Office 365, according to G2 Stack. Amphivena Therapeutics is actively using 9 …See details»

Amphivena Therapeutics, Inc. | CipherBio

Explore Amphivena Therapeutics, Inc.'s investment information, scientific platforms, therapeutic approaches, indications and more here!See details»

AMV300 - Drug Targets, Indications, Patents - Synapse

AMV300, Initially developed by Amphivena Therapeutics, Inc., Now, its global highest R&D status is Pending, Therapeutic Areas: Neoplasms.See details»

Amphivena Presents New Monotherapy and First Combination …

Jun 4, 2021 Amphivena has raised $88.5 M to date in Series A, B and C venture financings led by NanoDimension, Qiming Venture Partners USA, MPM Capital and funds managed by Tekla …See details»

Amphivena Therapeutics - Crunchbase

Amphivena Therapeutics is a clinical-stage immuno-oncology company that develops a platform of dual-function biologics. Search Crunchbase. ... Solutions. Products. Resources. Pricing. …See details»

Amphivena closes $62m Series C financing to expand clinical …

Amphivena Therapeutics, Inc., a private clinical stage immuno-oncology company developing T cell engager therapeutics for cancer, announced today the closing of a $62 million Series C …See details»

Novel AML patient selection assay for AMV564, Amphivena's lead …

Dec 6, 2020 SOUTH SAN FRANCISCO, Calif., Dec. 6, 2020 /PRNewswire/ --Amphivena Therapeutics, a clinical-stage oncology company focused on developing immunotherapeutics …See details»

Amphivena Therapeutics - Updates, News, Events, Signals & Triggers

Amphivena Therapeutics is focused on developing biologics for immuno-oncology, specifically targeting acute myeloid leukemia (AML) and solid tumors. Their research includes methods …See details»

linkstock.net © 2022. All rights reserved